Literature DB >> 23633290

Superparamagnetic iron oxide nanoparticles for MRI: contrast media pharmaceutical company R&D perspective.

Claire Corot1, David Warlin.   

Abstract

Superparamagnetic iron oxide (SPIO) nanoparticles are a relatively large class of contrast agents for magnetic resonance imaging. According to their biodistribution, distinct classes of SPIO nanoparticles have been investigated for clinical applications either as macrophage imaging agents or blood pool agents. Contrast agents which are pharmaceutics followed the same development rules as therapeutic drugs. Several drawbacks such as clinical development difficulties, organization of market access and imaging technological developments have limited the widespread use of these products. SPIO nanoparticles that are composed of thousands iron atoms providing large T2* effects are particularly suitable for theranostic. Stem cell migration and immune cell trafficking, as well as targeted SPIO nanoparticles for molecular imaging studies are mainly at the stage of proof of concept. A major economic challenge in the development of molecular imaging associated with a therapeutic treatment/procedure is to define innovative business models compatible with the needs of all players taking into account that theranostic solutions are promising to optimize resource allocation and ensure that expensive treatments are prescribed to responding patients.
© 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23633290     DOI: 10.1002/wnan.1225

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol        ISSN: 1939-0041


  15 in total

1.  Exponential growth of publications on carbon nanodots by Chinese authors.

Authors:  Junqing Wang; Hak Soo Choi; Yì-Xiáng J Wáng
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

2.  A targeted approach to cancer imaging and therapy.

Authors:  Chun Li
Journal:  Nat Mater       Date:  2014-02       Impact factor: 43.841

Review 3.  Oligonucleotide-based theranostic nanoparticles in cancer therapy.

Authors:  Reza Shahbazi; Bulent Ozpolat; Kezban Ulubayram
Journal:  Nanomedicine (Lond)       Date:  2016-04-22       Impact factor: 5.307

Review 4.  Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art.

Authors:  Luisa Fiandra; Amedeo Capetti; Luca Sorrentino; Fabio Corsi
Journal:  J Neuroimmune Pharmacol       Date:  2016-11-10       Impact factor: 4.147

5.  Theranostics and contrast-agents for medical imaging: a pharmaceutical company viewpoint.

Authors:  Jean-Marc Idée; Stéphanie Louguet; Sébastien Ballet; Claire Corot
Journal:  Quant Imaging Med Surg       Date:  2013-12

Review 6.  Analysis of FDA-approved imaging agents.

Authors:  Michael S Kinch; Pamela K Woodard
Journal:  Drug Discov Today       Date:  2017-03-21       Impact factor: 7.851

Review 7.  A comprehensive literatures update of clinical researches of superparamagnetic resonance iron oxide nanoparticles for magnetic resonance imaging.

Authors:  Yì Xiáng J Wáng; Jean-Marc Idée
Journal:  Quant Imaging Med Surg       Date:  2017-02

8.  In vivo nanoparticle imaging of innate immune cells can serve as a marker of disease severity in a model of multiple sclerosis.

Authors:  Klara Kirschbaum; Jana K Sonner; Matthias W Zeller; Katrin Deumelandt; Julia Bode; Rakesh Sharma; Thomas Krüwel; Manuel Fischer; Angelika Hoffmann; Milene Costa da Silva; Martina U Muckenthaler; Wolfgang Wick; Björn Tews; John W Chen; Sabine Heiland; Martin Bendszus; Michael Platten; Michael O Breckwoldt
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-31       Impact factor: 11.205

9.  Imaging the delivery of drug-loaded, iron-stabilized micelles.

Authors:  Suzanne J Bakewell; Adam Carie; Tara L Costich; Jyothi Sethuraman; J Edward Semple; Bradford Sullivan; Gary V Martinez; William Dominguez-Viqueira; Kevin N Sill
Journal:  Nanomedicine       Date:  2017-01-20       Impact factor: 5.307

10.  Impact of Serum Proteins on MRI Contrast Agents: Cellular Binding and T2 relaxation.

Authors:  Alexandra Hill; Christine K Payne
Journal:  RSC Adv       Date:  2014       Impact factor: 3.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.